See more : PetroNeft Resources plc (P8ET.IR) Income Statement Analysis – Financial Results
Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Maire Tecnimont S.p.A. (MAIRE.MI) Income Statement Analysis – Financial Results
- Perfectpac Limited (PERFEPA.BO) Income Statement Analysis – Financial Results
- Jiangsu Xiehe Electronic Co.,Ltd. (605258.SS) Income Statement Analysis – Financial Results
- BingEx Limited (FLX) Income Statement Analysis – Financial Results
- Centenary United Holdings Limited (1959.HK) Income Statement Analysis – Financial Results
STAAR Surgical Company (STAA)
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.42M | 284.39M | 230.47M | 163.46M | 150.19M | 123.95M | 90.61M | 82.43M | 77.12M | 74.99M | 72.22M | 63.78M | 62.77M | 54.96M | 75.35M | 74.89M | 59.36M | 56.28M | 51.30M | 51.69M | 50.46M | 48.25M | 50.24M | 53.99M | 59.00M | 54.20M | 42.50M | 42.20M | 34.70M | 27.40M | 20.10M | 10.20M | 4.30M | 4.50M | 4.50M | 6.80M |
| Cost of Revenue | 69.76M | 61.01M | 51.84M | 45.10M | 38.23M | 32.44M | 26.33M | 24.06M | 24.40M | 26.16M | 21.91M | 19.49M | 20.40M | 19.88M | 33.45M | 34.79M | 30.10M | 29.85M | 27.52M | 25.54M | 22.62M | 24.10M | 28.20M | 22.60M | 18.70M | 14.10M | 6.80M | 7.90M | 6.90M | 4.80M | 3.10M | 2.40M | 2.00M | 2.00M | 7.20M | 8.00M |
| Gross Profit | 252.65M | 223.38M | 178.64M | 118.36M | 111.95M | 91.51M | 64.28M | 58.37M | 52.72M | 48.82M | 50.31M | 44.29M | 42.37M | 35.08M | 41.89M | 40.11M | 29.27M | 26.43M | 23.79M | 26.14M | 27.84M | 24.15M | 22.03M | 31.39M | 40.30M | 40.10M | 35.70M | 34.30M | 27.80M | 22.60M | 17.00M | 7.80M | 2.30M | 2.50M | -2.70M | -1.20M |
| Gross Profit Ratio | 78.36% | 78.55% | 77.51% | 72.41% | 74.54% | 73.83% | 70.94% | 70.81% | 68.36% | 65.11% | 69.67% | 69.44% | 67.50% | 63.82% | 55.60% | 53.55% | 49.30% | 46.97% | 46.36% | 50.58% | 55.17% | 50.05% | 43.86% | 58.14% | 68.31% | 73.99% | 84.00% | 81.28% | 80.12% | 82.48% | 84.58% | 76.47% | 53.49% | 55.56% | -60.00% | -17.65% |
| Research & Development | 44.40M | 35.98M | 33.86M | 31.92M | 25.30M | 22.03M | 19.12M | 20.29M | 14.76M | 12.36M | 6.71M | 6.44M | 5.87M | 5.72M | 5.89M | 7.94M | 6.71M | 7.08M | 5.57M | 6.25M | 5.12M | 4.02M | 3.80M | 4.22M | 4.30M | 3.60M | 3.90M | 4.10M | 3.30M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.32M | 54.74M | 44.14M | 33.91M | 29.31M | 24.29M | 20.67M | 22.25M | 19.60M | 18.48M | 18.81M | 17.79M | 15.99M | 14.08M | 15.71M | 15.73M | 12.95M | 9.34M | 9.34M | 9.34M | 9.34M | 0.00 | 8.75M | 8.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 107.83M | 88.86M | 67.29M | 45.76M | 45.49M | 38.60M | 28.13M | 28.48M | 23.70M | 25.88M | 23.89M | 21.28M | 17.73M | 17.18M | 24.26M | 27.05M | 23.72M | 19.51M | 19.51M | 19.51M | 19.51M | 0.00 | 20.04M | 21.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.15M | 143.60M | 111.44M | 79.68M | 74.80M | 62.89M | 48.80M | 50.73M | 43.30M | 44.36M | 42.70M | 39.07M | 33.72M | 31.25M | 39.97M | 42.78M | 36.67M | 33.29M | 29.03M | 30.06M | 29.24M | 25.79M | 28.79M | 43.62M | 27.80M | 25.50M | 19.00M | 17.80M | 15.90M | 13.10M | 14.20M | 11.60M | 12.90M | 6.10M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.26M | 967.00K | 396.00K | 703.00K | 715.00K | 628.00K | 470.00K | 759.00K | 381.00K | 486.00K | 822.00K | 0.00 | 700.00K | -238.00K | 9.77M | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| Operating Expenses | 224.55M | 179.58M | 145.30M | 111.59M | 100.10M | 84.92M | 67.91M | 71.02M | 58.06M | 56.85M | 49.61M | 45.51M | 39.59M | 37.68M | 45.62M | 60.49M | 43.39M | 40.04M | 34.60M | 36.30M | 34.36M | 31.26M | 32.59M | 51.57M | 36.30M | 33.50M | 26.40M | 24.20M | 20.70M | 17.10M | 15.10M | 12.40M | 13.50M | 6.60M | 900.00K | 1.50M |
| Cost & Expenses | 294.32M | 240.59M | 197.13M | 156.69M | 138.33M | 117.36M | 94.24M | 95.09M | 82.46M | 83.01M | 71.52M | 65.00M | 59.98M | 57.56M | 79.07M | 95.28M | 73.48M | 69.88M | 62.12M | 61.84M | 56.98M | 55.36M | 60.79M | 74.17M | 55.00M | 47.60M | 33.20M | 32.10M | 27.60M | 21.90M | 18.20M | 14.80M | 15.50M | 8.60M | 8.10M | 9.50M |
| Interest Income | 0.00 | 2.45M | 38.00K | 238.00K | 988.00K | 165.00K | 0.00 | 3.00K | 50.00K | 51.00K | 59.00K | 59.00K | 32.00K | 43.00K | 60.00K | 160.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.45M | 0.00 | 0.00 | 0.00 | 165.00K | 0.00 | 115.00K | 128.00K | 154.00K | 170.00K | 291.00K | 523.00K | 896.00K | 1.33M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 4.51M | 3.64M | 3.10M | 3.70M | 2.46M | 3.35M | 2.89M | 2.40M | 2.46M | 2.15M | 1.96M | 2.27M | 2.41M | 3.74M | 3.64M | 2.51M | 2.37M | 2.47M | 2.69M | 2.90M | 3.10M | 3.62M | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| EBITDA | 33.22M | 48.31M | 36.98M | 9.86M | 15.55M | 9.06M | -277.00K | -9.66M | -3.08M | -5.14M | 3.44M | 1.75M | 5.49M | -379.00K | 364.00K | -17.13M | -12.19M | -10.88M | -7.32M | -7.34M | -3.62M | -4.01M | -6.93M | -16.45M | 8.20M | 11.00M | 12.80M | 12.40M | 8.60M | 6.80M | 2.80M | -3.80M | -10.60M | -3.60M | -2.70M | -1.20M |
| EBITDA Ratio | 10.30% | 17.59% | 17.33% | 5.51% | 10.70% | 7.98% | -1.21% | -11.27% | -2.76% | -6.85% | 4.70% | 2.54% | 8.10% | -0.28% | 0.10% | -22.15% | -18.54% | -20.45% | -17.06% | -14.63% | -6.12% | -4.81% | 1.54% | -21.19% | 13.39% | 19.00% | 23.06% | 27.96% | 23.05% | 21.90% | 10.45% | -63.73% | -244.19% | -313.33% | -60.00% | -19.12% |
| Operating Income | 28.10M | 43.80M | 33.34M | 6.77M | 11.85M | 6.60M | -3.63M | -12.66M | -5.34M | -8.03M | 700.00K | -1.22M | 2.78M | -2.60M | -3.73M | -20.39M | -14.12M | -13.60M | -10.81M | -10.16M | -6.53M | -7.11M | -17.79M | -20.18M | 4.00M | 6.60M | 9.30M | 10.10M | 7.10M | 5.50M | 1.90M | -4.60M | -11.20M | -4.10M | -3.60M | -2.70M |
| Operating Income Ratio | 8.71% | 15.40% | 14.47% | 4.14% | 7.89% | 5.32% | -4.01% | -15.35% | -6.92% | -10.70% | 0.97% | -1.91% | 4.43% | -4.73% | -4.95% | -27.22% | -23.78% | -24.17% | -21.07% | -19.65% | -12.93% | -14.74% | -35.40% | -37.38% | 6.78% | 12.18% | 21.88% | 23.93% | 20.46% | 20.07% | 9.45% | -45.10% | -260.47% | -91.11% | -80.00% | -39.71% |
| Total Other Income/Expenses | 5.60M | 1.75M | -2.04M | 1.50M | 1.17M | 44.00K | 1.34M | 211.00K | -268.00K | -618.00K | 414.00K | 701.00K | -79.00K | -1.08M | -741.00K | -1.29M | -1.04M | 95.00K | 854.00K | -88.00K | -705.00K | -1.01M | 2.99M | -5.30M | -900.00K | -500.00K | 2.40M | 100.00K | 300.00K | 600.00K | 700.00K | 2.70M | -100.00K | 10.00M | 0.00 | -800.00K |
| Income Before Tax | 33.70M | 45.80M | 31.30M | 8.27M | 13.03M | 6.64M | -2.30M | -12.44M | -5.61M | -8.65M | 1.11M | -519.00K | 2.70M | -3.68M | -4.71M | -21.67M | -15.16M | -13.51M | -9.96M | -10.25M | -7.16M | -8.12M | -18.24M | -25.48M | 3.10M | 6.10M | 11.70M | 10.20M | 7.40M | 6.10M | 2.60M | -1.90M | -11.30M | 5.90M | 0.00 | -3.50M |
| Income Before Tax Ratio | 10.45% | 16.11% | 13.58% | 5.06% | 8.67% | 5.36% | -2.53% | -15.10% | -7.27% | -11.53% | 1.54% | -0.81% | 4.31% | -6.70% | -6.25% | -28.94% | -25.53% | -24.00% | -19.41% | -19.82% | -14.19% | -16.84% | -36.31% | -47.20% | 5.25% | 11.25% | 27.53% | 24.17% | 21.33% | 22.26% | 12.94% | -18.63% | -262.79% | 131.11% | 0.00% | -51.47% |
| Income Tax Expense | 12.35M | 6.80M | 6.80M | 2.35M | -1.02M | 1.67M | -157.00K | -315.00K | 928.00K | -253.00K | 716.00K | 1.24M | 1.36M | 432.00K | 1.49M | 1.52M | 843.00K | 1.54M | 1.24M | 1.06M | 1.13M | 8.96M | -3.55M | -6.58M | 900.00K | 2.00M | 4.30M | 3.30M | -100.00K | -2.20M | 100.00K | 500.00K | 100.00K | 2.60M | 800.00K | 200.00K |
| Net Income | 21.35M | 39.67M | 27.51M | 5.91M | 14.05M | 4.97M | -2.14M | -12.13M | -6.53M | -8.39M | 398.00K | -1.76M | 1.35M | 53.00K | -6.20M | -23.20M | -16.00M | -15.04M | -11.18M | -11.33M | -8.36M | -17.16M | -14.83M | -18.90M | 2.20M | 2.40M | 7.40M | 6.90M | 7.50M | 8.30M | 2.50M | -5.10M | -11.30M | 3.50M | -4.40M | -3.80M |
| Net Income Ratio | 6.62% | 13.95% | 11.94% | 3.62% | 9.35% | 4.01% | -2.36% | -14.71% | -8.47% | -11.19% | 0.55% | -2.76% | 2.15% | 0.10% | -8.23% | -30.97% | -26.95% | -26.73% | -21.78% | -21.93% | -16.56% | -35.56% | -29.53% | -35.01% | 3.73% | 4.43% | 17.41% | 16.35% | 21.61% | 30.29% | 12.44% | -50.00% | -262.79% | 77.78% | -97.78% | -55.88% |
| EPS | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.18 | 0.57 | 0.50 | 0.55 | 0.84 | 0.21 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| EPS Diluted | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.17 | 0.53 | 0.50 | 0.55 | 0.80 | 0.20 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| Weighted Avg Shares Out | 48.52M | 47.99M | 47.21M | 45.61M | 44.49M | 45.16M | 41.00M | 40.33M | 38.43M | 38.09M | 36.71M | 35.26M | 35.43M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.14M | 17.00M | 15.37M | 14.67M | 13.33M | 12.98M | 13.80M | 13.64M | 9.88M | 11.90M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
| Weighted Avg Shares Out (Dil) | 49.43M | 49.38M | 49.46M | 47.95M | 46.90M | 45.26M | 41.00M | 40.33M | 39.26M | 38.09M | 38.61M | 36.25M | 36.88M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.16M | 17.00M | 15.37M | 14.67M | 14.12M | 13.96M | 13.80M | 13.64M | 10.38M | 12.50M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
STAAR Surgical to Participate in BTIG Ophthalmology Day
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and...
A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - Chair, President and CEO Patrick Williams - CFO Conference Call Participants Tom Stephan -...
CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC...
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.30 per share a year ago.
STAAR Surgical Reports Third Quarter 2024 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27,...
STAAR Surgical to Report Third Quarter Results on October 30, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third...
Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher
Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher...
Fast Money traders share their favorite stocks of the week
Fast Money traders Steve Grasso, Tim Seymour, Julie Biel, and Mike Khouw share their favorite stocks from this week and explain the reasoning behind their choices.
Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know
The mean of analysts' price targets for Staar Surgical (STAA) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Source: https://incomestatements.info
Category: Stock Reports